Pulse Biosciences, Inc (PLSE): Price and Financial Metrics


Pulse Biosciences, Inc (PLSE): $1.95

0.07 (+3.72%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

PLSE POWR Grades

  • Growth is the dimension where PLSE ranks best; there it ranks ahead of 51.86% of US stocks.
  • PLSE's strongest trending metric is Growth; it's been moving down over the last 178 days.
  • PLSE's current lowest rank is in the Value metric (where it is better than 3.54% of US stocks).

PLSE Stock Summary

  • With a price/sales ratio of 43.87, PULSE BIOSCIENCES INC has a higher such ratio than 96.05% of stocks in our set.
  • With a year-over-year growth in debt of 523.82%, PULSE BIOSCIENCES INC's debt growth rate surpasses 96.51% of about US stocks.
  • PULSE BIOSCIENCES INC's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -116.56%, greater than the shareholder yield of only 4.93% of stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to PULSE BIOSCIENCES INC are VNRX, BLI, BFLY, IPWR, and NSPR.
  • Visit PLSE's SEC page to see the company's official filings. To visit the company's web site, go to www.pulsebiosciences.com.

PLSE Valuation Summary

  • In comparison to the median Healthcare stock, PLSE's price/earnings ratio is 104.74% lower, now standing at -1.1.
  • Over the past 79 months, PLSE's price/sales ratio has gone NA NA.

Below are key valuation metrics over time for PLSE.

Stock Date P/S P/B P/E EV/EBIT
PLSE 2022-11-25 45.1 11.3 -1.1 -1.2
PLSE 2022-11-23 43.9 11.0 -1.1 -1.1
PLSE 2022-11-22 42.4 10.6 -1.0 -1.1
PLSE 2022-11-21 41.5 10.4 -1.0 -1.1
PLSE 2022-11-18 46.0 11.6 -1.1 -1.2
PLSE 2022-11-17 46.5 11.7 -1.1 -1.2

PLSE Growth Metrics

    Its 3 year net cashflow from operations growth rate is now at -121.32%.
  • Its year over year cash and equivalents growth rate is now at -78.83%.
  • Its 5 year net income to common stockholders growth rate is now at -412.35%.
PLSE's revenue has moved up $1,553,000 over the prior 33 months.

The table below shows PLSE's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 1.553 -51.742 -64.724
2022-06-30 2.127 -54.46 -60.967
2022-03-31 1.862 -58.004 -62.294
2021-12-31 1.418 -54.097 -63.66
2021-09-30 0.574 -50.658 -61.994
2021-06-30 0 -45.857 -60.608

PLSE's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • PLSE has a Quality Grade of D, ranking ahead of 20.2% of graded US stocks.
  • PLSE's asset turnover comes in at 0 -- ranking 171st of 186 Medical Equipment stocks.
  • BBLG, SNN, and EYE are the stocks whose asset turnover ratios are most correlated with PLSE.

The table below shows PLSE's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0 NA -1.553
2021-03-31 0 NA -1.555
2020-12-31 0 NA -1.854
2020-09-30 0 NA -1.789
2020-06-30 0 NA -1.916
2020-03-31 0 NA -1.617

PLSE Price Target

For more insight on analysts targets of PLSE, see our PLSE price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $38.00 Average Broker Recommendation 1.33 (Strong Buy)

PLSE Stock Price Chart Interactive Chart >

Price chart for PLSE

PLSE Price/Volume Stats

Current price $1.95 52-week high $21.64
Prev. close $1.88 52-week low $1.18
Day low $1.77 Volume 70,100
Day high $1.99 Avg. volume 196,417
50-day MA $2.03 Dividend yield N/A
200-day MA $2.61 Market Cap 72.59M

Pulse Biosciences, Inc (PLSE) Company Bio


Pulse Biosciences, a development stage medical device company, focuses on developing medical technologies based on sub-microsecond pulsed electric field technology to detect and treat skin cancer and enhance wound healing. The company was founded in 2014 and is based in Burlingame, California.


PLSE Latest News Stream


Event/Time News Detail
Loading, please wait...

PLSE Latest Social Stream


Loading social stream, please wait...

View Full PLSE Social Stream

Latest PLSE News From Around the Web

Below are the latest news stories about PULSE BIOSCIENCES INC that investors may wish to consider to help them evaluate PLSE as an investment opportunity.

Pulse Biosciences Reports Third Quarter 2022 Financial Results

HAYWARD, Calif., November 10, 2022--Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company and creator of the unique CellFX® System which harnesses and effectively controls the application of Nano-Pulse Stimulation™ (NPS™) to human cells and tissue for ablation in multiple therapeutic conditions, today announced financial results for the third quarter ended September 30, 2022.

Yahoo | November 10, 2022

Pulse Biosciences Schedules Third Quarter 2022 Financial Results Conference Call for November 10, 2022

HAYWARD, Calif., October 27, 2022--Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technology, announced today it will report financial results for the third quarter of 2022 after market close on Thursday, November 10, 2022. Company management will host a corresponding conference call beginning at 1:30pm PT / 4:30pm ET.

Yahoo | October 27, 2022

Insider Buying: The Pulse Biosciences, Inc. (NASDAQ:PLSE) Chief Strategy Officer & Director Just Bought 70% More Shares

Even if it's not a huge purchase, we think it was good to see that Mitchell Levinson, the Chief Strategy Officer...

Yahoo | October 14, 2022

Pulse Biosciences Announces Positive Clinical Data on Nano-Pulse Stimulation Procedure for Low-Risk Basal Cell Carcinoma Lesions

HAYWARD, Calif., October 06, 2022--Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technology, today announced positive clinical data from an FDA approved Investigational Device Exempt treat and resect study on the use of NPS for low-risk basal cell carcinoma (BCC) lesions. An oral video presentation on the favorable results of performing the CellFX procedure for low-risk superficial and nod

Yahoo | October 6, 2022

Pulse Biosciences (NASDAQ:PLSE) adds US$29m to market cap in the past 7 days, though investors from a year ago are still down 89%

Pulse Biosciences, Inc. ( NASDAQ:PLSE ) shareholders will doubtless be very grateful to see the share price up 81% in...

Yahoo | October 1, 2022

Read More 'PLSE' Stories Here

PLSE Price Returns

1-mo -10.14%
3-mo 53.54%
6-mo -4.88%
1-year -90.61%
3-year -86.57%
5-year -90.97%
YTD -86.83%
2021 -37.93%
2020 77.93%
2019 17.02%
2018 -51.44%
2017 263.08%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7394 seconds.